I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or ...

Read the original article: shanghai china - BingNews